Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023
Selling, General & Admin	15.76	15.76	5.94	3.08	16.85
Research & Development	22.84	22.84	8.15	8.79	41.8
Total Operating Expenses	38.6	38.6	14.1	11.87	58.65
Operating Income	-38.6	-38.6	-14.1	-11.87	-58.65
Interest Income	-	-	-	6.27	-
Interest Expense	-5.82	-5.82	-4.32	-	-
Other Non-Operating Income (Expense)	-1.34	-0.61	-1.6	24.3	-
Total Non-Operating Income (Expense)	-7.16	-6.43	-5.92	30.56	-
Pretax Income	-45.76	-45.03	-20.01	18.69	-58.65
Net Income	-41.72	-41.72	-17.43	17.92	-24.54
Net Income Attributable to Preferred Dividends	-	-	-	0.78	-
Net Income to Common	-41.72	-41.72	-17.43	17.92	-24.54
Shares Outstanding (Basic)	11	11	2	2	1
Shares Outstanding (Diluted)	11	11	2	2	1
Shares Change (YoY)	1.88%	396.13%	24.08%	64.84%	-80.97%
EPS (Basic)	-3.71	-3.71	-7.83	2.19	2.19
EPS (Diluted)	-3.71	-3.71	-7.83	2.17	2.17
Shares Outstanding	12.38	11.06	11.01	1.24	1.24
Free Cash Flow	-25.01	-25.01	-10.84	-13.7	-53.82
Free Cash Flow Per Share	-2.22	-2.26	-4.87	-7.64	-49.45
EBITDA	-38.6	-38.6	-14.1	-11.87	-58.65
EBIT	-38.6	-38.6	-14.1	-11.87	-58.65

Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q